Microbiota, systemic immunity, and extracellular vesicles in stroke: peripheral nodes as therapeutic leverage points

Area of Science:

• Neuroscience
• Immunology
• Regenerative Medicine

Background:

• Stroke is increasingly recognized as a systemic disorder affecting multiple organs beyond the brain.
• Post-stroke stress responses can destabilize peripheral organ homeostasis, leading to immune and metabolic changes that worsen neuroinflammation.
• Immune responses after stroke are dynamic, with early inflammation potentially harming and later stages aiding repair, highlighting the importance of timing and balance.

Purpose of the Study:

• To propose a "periphery-first" therapeutic strategy using stem cell-derived extracellular vesicles (EVs) for stroke treatment.
• To reframe the low brain exposure of systemically administered EVs as an advantage by targeting peripheral organs.
• To leverage EV interactions with reticuloendothelial and barrier-associated organs to mitigate secondary brain injury.

Main Methods:

• Synthesizing evidence on stroke-induced multi-organ dysfunction and immune remodeling.
• Integrating mechanistic insights into how EVs can rebalance peripheral immunity and metabolism.
• Analyzing the role of EVs at the blood-brain barrier and within the central nervous system.

Main Results:

• Systemic administration of EVs can reprogram peripheral immune trajectories and strengthen barrier integrity.
• EVs can suppress humoral amplification loops that contribute to secondary brain injury.
• A periphery-first approach leverages natural EV sequestration in organs like the liver, spleen, and gut.

Conclusions:

• A periphery-first framework positions EV therapy as a systems-level intervention targeting peripheral drivers of secondary brain injury.
• Further research is needed to establish quantitative causal mechanisms for EV efficacy.
• Developing translation-ready manufacturing, dosing, and quality control principles is crucial for clinical development.